Zobrazeno 1 - 10
of 108
pro vyhledávání: '"M. Orlowska-Volk"'
Autor:
Urs-Nikolaus Riede, M. Orlowska-Volk
Publikováno v:
Springer-Lehrbuch ISBN: 9783662487242
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e06b76dd9182f5f1665be07425ebd4c
https://doi.org/10.1007/978-3-662-48725-9_62
https://doi.org/10.1007/978-3-662-48725-9_62
Autor:
Dominik Denschlag, M Orlowska-Volk, Maximilian Klar, Ingo Brink, Michaela Bossart, Elmar Stickeler
Publikováno v:
European Journal of Surgical Oncology (EJSO). 37:818-823
Aims Sentinel lymph node (SLN) mapping appears to be feasible in patients with primary vulvar cancer. Previous protocols describe the injection of the technetium-99m-nanocolloid at least 3 h before surgery which involves two invasive procedures for t
Publikováno v:
Geburtshilfe und Frauenheilkunde. 67:359-362
This is a report on a 42-year-old woman with a primary ovarian rhabdomyosarcoma, who presented with dyspnea and rapid abdominal distension. The abdominal mass was removed and after final histological and immunohistochemical analysis the initial froze
Autor:
Jörg Heil, Julia Kathrin Jueckstock, A. Hartmann, Ruediger Schulz-Wendtland, Peter A. Fasching, Elmar Stickeler, Lothar Häberle, Alexander Hein, M Orlowska-Volk, M. Windfuhr-Blum, C. Sohn, Brigitte Rack, Joachim Rom, Ulrich Andergassen, Maximilian Klar, M. W. Beckmann, Florian Schuetz, Wolfgang Janni, Tanja Fehm, Christian R. Loehberg, Claudia Rauh
Introduction: Use of hormone therapy (HT) has declined dramatically in recent years. Some studies have reported that HT use before a diagnosis of breast cancer (BC) may be a prognostic factor in postmenopausal patients. This study aimed to examine th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50d59cbf36b42c1bc6a6e1717be6c98f
https://europepmc.org/articles/PMC4490917/
https://europepmc.org/articles/PMC4490917/
Autor:
Charlotte M. Niemeyer, Barbara Selle, M Orlowska-Volk, Anke M.J. Peters, Ulrich Pannicke, Anselm Enders, W. Friedrich, Detlev Schindler, Ulrich Duffner, Elisabeth Nikolopoulos, Stephan Ehl, Klaus Schwarz, Paul Fisch
Publikováno v:
The Journal of Immunology. 176:5060-5068
DNA ligase IV (LigIV) deficiency was identified as the molecular basis for a severe form of combined immunodeficiency in two microcephalic siblings with cellular radiosensitivity. In one patient the diagnosis was made directly after birth, allowing a
Expression of the Transcriptional Coregulator FHL2 in Human Breast Cancer: A Clinicopathologic Study
Autor:
M. Orlowska-Volk, Schuele Roland Dr, Annettee Hasenburg, Judith Müller, Boris Gabriel, Axel zur Hausen, Dagmar-C Fischer
Publikováno v:
Journal of the Society for Gynecologic Investigation. 13:69-75
Although the Four and a Half LIM domain protein 2 (FHL2) has been suggested to play an important role in tumor development, this has not been investigated in breast cancer.Paraffin-embedded tissues from patients (n = 85) with primary breast cancer we
Autor:
Peter Bronsert, M Orlowska-Volk, Jose Alberto Villacorta Hidalgo, Annette Schmitt-Graeff, Gian Kayser, Martin Werner, Elmar Stickeler, Miroslav Malkovsky, Liliana B. Díaz, Paul Fisch
Publikováno v:
Frontiers in Immunology
Breast cancer is the leading cause of cancer death in women and the second most common cancer worldwide after lung cancer. The remarkable heterogeneity of breast cancers influences numerous diagnostic, therapeutic, and prognostic factors. Triple-nega
Autor:
Dirk Watermann, Elmar Stickeler, M Orlowska-Volk, Annette Hasenburg, A. zur Hausen, Gerald Gitsch, M Jäger, Boris Gabriel
Publikováno v:
British Journal of Cancer
The pp125 focal adhesion kinase (FAK) is involved in integrin-mediated cell signalling and overexpressed in a variety of solid tumours. Focal adhesion kinase expression has been correlated to invasion and metastasis, but the data on breast cancer are
Multipel rezidivierendes Pseudomyxoma peritonei: Herausforderungen einer individualisierten Therapie
Publikováno v:
Geburtshilfe und Frauenheilkunde. 65:418-422
Pseudomyxoma peritonei is a rare tumor entity with an inhomogenous prognosis. The 5-year survival rate varies between 6 and 84% depending on the histological subtype. We present the case of a 44-year-old woman with originally benign pseudomyxoma peri
Publikováno v:
European Clinics in Obstetrics and Gynaecology. 1:19-23